Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as CVC
Cenicriviroc · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Severe hepatic impairment | EXPERIMENTAL | Cenicriviroc tablet; single-dose oral administration |
| Normal Hepatic function | EXPERIMENTAL | Cenicriviroc tablet; single-dose oral administration |
| Name | Type | Description |
|---|---|---|
| Cenicriviroc | DRUG | 1 tablet; single-dose oral administration |
Inclusion Criteria for all participants: * Sign the ICF and have the mental capability to understand it * If female, have a negative result from a serum pregnancy test at screening and a negative result from a serum or urine pregnancy test on Day -1 * If male, agree to use an effective method of co...
Cenicriviroc is an investigational small molecule developed by AbbVie Inc. (ticker ABBV) for hepatic impairment. It is a CCR2 and CCR5 antagonist and has been studied in a Phase 1 clinical trial. It is not an approved therapy and remains in clinical development.
Cenicriviroc has been evaluated in hepatic impairment, specifically to assess how severe hepatic impairment affects the pharmacokinetics of the drug and its metabolites. The relevant study was a Phase 1 trial conducted in the United States. Cenicriviroc is investigational and has not been approved for any use.
Cenicriviroc targets CCR2 and CCR5, two chemokine receptors, and acts as an antagonist at both. By blocking these receptors, the small molecule interferes with CCR2 and CCR5 mediated signaling. This mechanism underlies its investigation in hepatic impairment.
Cenicriviroc is developed by AbbVie Inc., which trades under the ticker ABBV. AbbVie is the sponsor associated with the clinical development of this small molecule CCR2 and CCR5 antagonist. The drug remains investigational.
Cenicriviroc is in Phase 1 development. The single recorded trial, NCT03376841, was a Phase 1 study that has been completed. Cenicriviroc is investigational and is not FDA approved for any indication.
Cenicriviroc has been studied in one clinical trial, NCT03376841, titled Impact of Severe Hepatic Impairment on Pharmacokinetics of Cenicriviroc and Its Metabolites. It was a completed Phase 1 controlled study with 16 enrolled participants, conducted in the United States, and included healthy volunteers.